**                                                                                        EXHIBIT      10.2**

**MEDTECH      PRODUCTS, INC.**

**AND**

**PHARMACARE      LIMITED**

**AND**

**PRESTIGE      BRANDS HOLDINGS, INC. **

**AND**

**ASPEN      PHARMACARE HOLDINGS LIMITED**

**____________________________________________**

**Exclusive      Supply Agreement**

----

**Table      of Contents**

| 1.          | PARTIES    .......................................................................................................................................................................................................                                                                            | 1        |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 2.          | RECITAL    .......................................................................................................................................................................................................                                                                            |  1  |
| 3.               | INTERPRETATION................................................................................................................................................................................................                                                                                                    |  1  |
| 4.          | PREREQUISITE              CONDITIONS............................................................................................................................................................................                                                                                                  |  11 |
| 5.               | FACILITY    .....................................................................................................................................................................................................                                                                             |  12 |
| 6.               | INTERIM PERIOD AND              ALTAIRE.......................................................................................................................................................................                                                                                                    |  12 |
| 7.               | MATERIAL TERMS OF THE SUPPLY              AGREEMENT.........................................................................................................................................                                                                                                                      |  14 |
| 7.1              |                    *Supply*.......................................................................................................................................................................................................                                                       |  14 |
| 7.2         |                       *Right of First              Refusal*...............................................................................................................................................................................                                |  14 |
| 7.3              |                       *Purchase              price/s*.......................................................................................................................................................................................                              |  15 |
| 7.4              | *                      Forecasts/Firm              Orders*.............................................................................................................................................................................                                   |  17 |
| 7.5         | *                      Quantities of Supply and Exclusive              Purchase.*.........................................................................................................................................                                                |  18 |
| 7.6              |                       *Delivery*....................................................................................................................................................................................................                                      |  19 |
| 7.7              |                       *Specifications*...........................................................................................................................................................................................                                         |  19 |
| 7.8              |         *Acceptance of              Delivery*............................................................................................................................................................................                                                 |  20 |
| 7.9         |          *Terms              of              Sale*............................................................................................................................................................................................                       |  21 |
| 7.10             |                       *Medtech's Intellectual              Property*...............................................................................................................................................................                                       |  22 |
| 7.11             |               * Manufacturing              Issues*...............................................................................................................................................................................      |  23 |
| 7.12             |                       *Product Optimization and Line              Extensions*.............................................................................................................................................                                                |  24 |
| 7.13             |                       *Adverse Drug Reaction, Competent Authorities and Product              Recall*......................................................................................................                                                                |  25 |
| 7.14             |                       *Delivery of Know-How and Intellectual              Property*...................................................................................................................................                                                    |  25 |
| 7.15             |                       *Warranties by              Medtech*............................................................................................................................................................................                                    |  26 |
| 7.16             |          *Strategic              Plan*...........................................................................................................................................................................................                                    |  27 |
| 7.17             |                       *Regulatory              Support*..................................................................................................................................................................................                                 |  27 |
| 7.18             |                       *Liability*....................................................................................................................................................................................................                                     |  28 |
| 7.19   |                       *Remedies*...................................................................................................................................................................................................                                       |  29 |
| 7.20             |                *Subcontracting*.........................................................................................................................................................................................               |  33 |
| 7.21             | *                            Sale of Business by              Medtech*..................................................................................................................................................................... |  33 |
| 8.               | EFFECT OF TERMINATION OR              EXPIRATION..................................................................................................................................................                                                                                                                |  33 |
| 9.               | CONFIDENTIALITY..............................................................................................................................................................................................                                                                                                     |  34 |
| 10.         | RELATIONSHIP OF              PARTIES..............................................................................................................................................................................                                                                                                |  35 |
| 11.              | ASSIGNMENT........................................................................................................................................................................................................                                                                                                |  35 |
| 12.              | FORCE              MAJEURE..................................................................................................................................................................................................                                                                                      |  35 |
| 13.              | GOVERNING LAW AND              JURISDICTION...........................................................................................................................................................                                                                                                            |  36 |
| 14.              | NOTICES................................................................................................................................................................................................................                                                                                           |  36 |
| 15.              | ANNOUNCEMENT...............................................................................................................................................................................................                                                                                                       |  37 |
| 16.         | PRESTIGE              SURETYSHIP.......................................................................................................................................................................................                                                                                           |  37 |
| 17.              | ASPEN              SURETYSHIP............................................................................................................................................................................................                                                                                         |  38 |
| 18.              | AFFILIATES............................................................................................................................................................................................................                                                                                            |  40 |
| 19.         | COSTS.....................................................................................................................................................................................................................                                                                                        |  40 |

| EXHIBIT A    | -  Primary              Packaging              Schedules                   | 42       |
|--------------|-------------------------------------------------------------------------------------------|----------|
| EXHIBIT B    | -  Products,              Territory and              Delivery Destination  |  43 |
| EXHIBIT C    | -  Quality              Agreement                                          |  44 |
| EXHIBIT D    | -  Purchase              Price/s                                           |  52 |
| APPENDIX QA1 | -  Product              Names, Strengths              and Sizes            |  53 |
|         |                                                                                      |     |

 

----

| 1.        ** ** | **PARTIES** |
|--------------------------------------------------------------|-------------|

| 1.1.       | Medtech                Products, Inc., a Delaware Corporation having its principal place                of                business at 90 North Broadway, Irvington, New York, 10533, United                States of America (“Medtech”); |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2.       | Pharmacare                Limited, a company registered and incorporated in the Republic of                South                Africa having its principal place of business at Building 8 Healthcare                Park, Woodlands Drive, Woodmead, Johannesburg, Republic of South                Africa                (“Pharmacare”); |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3.       | Prestige                Brands Holdings, Inc., a Delaware Corporation having its principal                office                at 90 North Broadway, Irvington, New York 10533, United States of                America                (“Prestige”); |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.4.       | Aspen                Pharmacare Holdings Limited, a company registered and incorporated                in the                Republic of South Africa having its principal place of business at                Building 8 Healthcare Park, Woodlands Drive, Woodmead, Johannesburg,                Republic of South Africa (“Aspen”). |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.          | **RECITAL** |
|----------------------------------------------------------|-------------|

| 2.1.       | Medtech                and                Pharmacare are entering into this supply agreement with regard to                the                manufacture and supply by Pharmacare of the products (as defined                below) to                Medtech and certain ancillary issues.                This supply agreement is intended to be exclusive in the United States                and                Canada except as specifically provided herein. This supply agreement                is                not intended to be exclusive outside the United States and Canada                unless                specifically provided herein. |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2.       | Pharmacare                is a wholly owned subsidiary of                Aspen. |
|------------------------------------------|---------------------------------------------------------------------------------|

| 2.3.       | Medtech                is a wholly owned subsidiary of                Prestige. |
|------------------------------------------|---------------------------------------------------------------------------------|

| 3.          | **INTERPRETATION** |
|----------------------------------------------------------|--------------------|

----

|  3.1.       |                                                                                                         4clause                headings are for convenience and shall not be used in its interpretation                unless the context clearly indicates a contrary intention                - |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.1.                | an                expression which denotes the singular includes the plural and *vice                versa*; |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|

| 3.1.2.                | the                following expressions bear the meanings assigned to them below and                cognate                expressions bear corresponding meanings                - |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.1.                         | “this                **agreement**”                means this agreement and its Exhibits, as amended, from time to                time; |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.2.                       ** ** | **“adverse                event”**                means any untoward medical occurrence that may present during treatment                with a medicine, but which does not necessarily have a causal relationship                with this treatment; |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.3.                         | **“affiliate/s****”**                means an entity, (whether or not incorporated and including without                any                limitation, a company, corporation, trust, partnership, joint venture                or                other association of persons) which, presently or in the                future - |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.3.1.                                  | is                owned or controlled by a party hereto by way of ownership, directly                or                indirectly, of 20% or more of such entity’s share capital or otherwise,                and such an entity shall continue to be deemed an affiliate only                as long                as such ownership or control continues;                or |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.3.2.                                  | owns                or controls a party hereto by way of ownership, directly or indirectly,                of                20% or more of such party’s share capital or otherwise, and such an entity                shall continue to be an affiliate only for so long as such ownership                or                control continues; |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.4.                         | **“Altaire****”**                means Altaire Pharmaceuticals Inc., a Delaware Corporation having                its                principal place of business at 91-1 Colin Drive, Holbrook, New York                11741,                Voice 516-472-8186; Fax                516-472-8256; |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                      5 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3.1.2.5.                         | **“applicable                laws****”**                means in relation to any person or entity, all or any laws compliance                with                which is mandatory for that person or                entity; |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.6.                        | **“bulks****”**                means bulk batches of the manufactured products prior to their primary                packaging; |
|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.7.                        | **“current                good manufacturing practice or cGMP’s****”**                means the regulatory and other standards of good manufacturing practice                relating to the manufacture of medicinal products as directed in                the Code                of Federal Regulations 21 CFR, Parts 210 and 211 and the Guidance                for                Industry: cGMP’s; |
|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.8.                        | **“commission/commissioned****”**                means the stage at which government or regulatory authority has been                granted and the facility is capable of commencing manufacture of                the                products; |
|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.9.                        | **“confidential                information”**                means information of a confidential and proprietary nature as defined                in                **clause                9**; |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.10.                      | **“****effective                date”**means                the date upon which this agreement is signed by the party which signs                it                last in time; |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.11.                      | **“exclusive                supply term****”**                means the period commencing on 1 January 2009 and terminating on 31                December 2013 and the extended period/s (if                any); |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.12.                      | **“extended                period/s****”**                has the meaning given to that term in **clause                3.1.2.44**; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.13.                      | **“ex-works****”**                means ex-works as determined in accordance with INCOTERMS                2000; |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.14.                      | **“facility****”**                means the eye drop manufacturing facility which is in the process                of being                constructed by Pharmacare in Port Elizabeth, Republic of South Africa,                for                the purposes of, *inter                alia*,                manufacturing the products; |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                                   6 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3.1.2.15.                      | **“FDA****”**                means the United States Department of Health and Human Services,                Food and                Drug Administration; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.16.                      | **“****firm                order”**has                the meaning given to that term in **clause                7.4;** |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.17.                      | **“firm                order period”**                has the meaning given to that term in **clause                7.4;** |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.18.                      | **“force                majeure event”**                means an event which interferes with the ability of a party to perform                its                obligations or duties under the supply agreement which is not within                the                reasonable control of the party affected, not due to malfeasance,                and                which could not with the exercise of due diligence have been avoided,                including fire, accident, labour difficulty, strike, riot, civil                commotion, act of God, delay or change in                law; |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.19.                      | **“governmental                or regulatory authority”**                means any court, tribunal, arbitrator, agency, commission, official,                department, inspectorate, ministry, parliament or public or statutory                person or other instrumentality of any relevant country, state, province,                county, city or other political subdivision having jurisdiction over                any                of the activities contemplated by the supply agreement and for the                avoidance of doubt shall include the                FDA; |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.20.                      | **“interim                period****”**                means the period from the effective date until 31 December                2008; |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.21.                      | **“intellectual                property****”**                means the body of technical information that is secret and substantial                and                comprises the formulae, specific manufacturing and packaging instructions                (including but not limited to information, formulations, instructions,                specifications and methods of quality control) but excluding the                trademarks and patents; |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.22.                      | **“inventory”**                means raw materials and packaging components for the                products; |
|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              7 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3.1.2.23.                      | **“know-how”**                means the scientific and technical practices developed or owned by                Medtech                that are secret and substantial as well as any knowledge or the right                to                have the knowledge relating to the intellectual property imparted                and                comprises techniques and processes which are inherent and necessary                to                manufacture the products so as to enable Pharmacare to so manufacture                the                products; |
|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.24.                      | **“laws”**                means all laws, statutes, rules, regulations, ordinances, guidelines                and                other pronouncements having the effect of law of any relevant governmental                or regulatory authority; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.25.                      | **“latent                defect”**                means a defect (a) existing at the time of receipt of the products                by                Medtech which is not discovered by visual inspection of the products                by                Medtech (or could not have been discovered by visual inspection in                accordance with **clause                7.8.1**                of                this agreement); but excluding (b) (i) a defect arising after the                transfer                of risk in the products including a defect resulting from the storage,                handling or transport of the products following the transfer of risk;                and                (ii) a defect which is attributable to any specifications or instructions                received from Medtech; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.26.                      | **“manufacture”**means                all the activities relating to the production of each product spanning                from purchasing the inventory to production, quality control and                assurance, filling, labelling, packaging and finishing, release,                holding                and storage and the tests and analyses conducted in connection                therewith; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.27.                      | **“manufacturing                authorisation”**                means the authorisation to manufacture the products as granted by                the                relevant governmental or regulatory                authorities; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.28.                      | **“marketing                authorisation”**                means those product licences and product authorisations relating                to the                products which enable the sale of the products in any part of the                territory as granted by the relevant governmental or regulatory                authorities; |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                      8 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3.1.2.29.                      | **“Medtech’s                requirements of the products****”**                means the total volume of the products which Medtech and/or its                affiliates, directly or indirectly, market, distribute and/or sell                in the                territory; |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.30.                      | **“party”**                means either Medtech or Pharmacare and **“parties”**                shall mean both Medtech and                Pharmacare; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.31.                      | **“****patents”**means                any unexpired and otherwise valid patent issued by the United States                Patent and trademark Office licensed, owned or applied for by Medtech                or                its affiliates pertaining to the products and used in their                manufacture; |
|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.32.                      | **“primary                packaging****”**                means the packaging that constitutes the final packed individual                product                unit in a form suitable for sale to retailers which, as at the effective                date, consist of the packaging specifications set out in                **Exhibit                A;** |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.33.                      | **“prime                rate****”**                means the minimum overdraft rate (percent per annum, compounded monthly)                from time to time published by the Standard Bank of South Africa                Limited                as being its minimum overdraft rate to its prime customers in the                private                sector, as certified by any manager of that bank, whose designation                need                not be proved; |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.34                    | **                  “****product”**means                the products described in **column                1**                of                **Exhibit                B;** |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.35.                      | **“****quality                agreement”**means                the quality agreement which stands to be executed between the parties                in                relation to the delineation of technical and quality assurance                responsibilities of the parties, which agreement will be substantially                in                accordance with the pro-forma quality agreement, annexed hereto marked                **Exhibit                C;** |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.36.                      | **“regulatory                support****”**                means the allocation, in the Republic of South Africa, of one suitably                qualified representative of Pharmacare to assist Medtech in undertaking                the compliance activities and processes relating to the maintenance                and                updating |
|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                      9 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|                 | of the marketing authorisations in so far as the activities relate              to              the purchasing of inventory, production, quality control and assurance,              filling, labelling, packaging and finishing, release, holding and storage              of the products; under the direct supervision, instruction and control              and              at the risk of Medtech and which includes the grant of the rights of              use              to Medtech of Pharmacare’s equipment and consumables incidental              thereto; |
|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 3.1.2.37.                      | **“rolling                forecast”**                has the meaning given to that term in **clause                7.4.1;** |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.38.                      | **“secondary                packaging****”**                means the packaging that constitutes the outer packaging (including                but                not limited to shrink wrap and pallets) used to transport and store                the                products; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.39.                      | **“serious                adverse event”**                means any untoward medical occurrence that at any                dose: |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.39.1.                               | results                in death; |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|

| 3.1.2.39.2.                               | is                life-threatening, in that the patient is at risk of death at any                time of                the event; |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.39.3.                               | requires                patient hospitalisation or prolongation of existing                hospitalisation; |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|

| 3.1.2.39.4.                               | results                in persistent or significant disability/incapacity;                or |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|

| 3.1.2.39.5.                               | results                in a congenital abnormality/birth                defect; |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|

| 3.1.2.40.                      | **“specifications”**                means the specifications applicable to the products as recorded in                their                respective marketing                authorisations; |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.41.                      | **“stability                services****”**                means all activities and processes necessary to validate the products                shelf life in accordance with the stability protocol recorded in                the                technical agreement; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                      10 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3.1.2.42.                    ** ** | **“strategic                plan****”**                means the strategic plan referred to in **clause                7.16;** |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.43.                      | **“territory”**                means the United States and Canada. The territory may be expanded                or                contracted from time to time by written agreement between the                parties; |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.44.                      | **“term”**                means the period commencing on the effective date and terminating                on 31                December 2013 (“the initial period”) which agreement will be automatically                extended for consecutive periods of 5 (five) years each (“the extended                periods”) on the same terms and subject to the same conditions set out in                the supply agreement unless either party gives the other party written                notice of its intention to terminate the supply agreement, which                notice                shall be given at least 18 (eighteen) months prior to the expiry                of the                initial period or any of the extended periods (as the case may                be); |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.45.                       | **“trademarks”**                means Medtech’s name and logo and other trademarks (including but not                limited to Murine and Clear Eyes) it wishes to include on the                products; |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.46.                       | **“validation/validated****”**                means the process of establishing documented evidence which produces                a                high degree of assurance that a specific process will consistently                produce                the bulks in a form which will meet their pre-determined specifications                and quality attributes. |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.         | **PREREQUISITE                CONDITIONS** |
|----------------------------------------------------|--------------------------------------------|

| 4.1.       | This                agreement (other than 1, 2, 3, this 4 and 9 to 19, by which the parties                shall immediately be bound) is subject to fulfilment of the prerequisite                antecedent conditions that by no later than midnight (South African                time)                on 21 September 2006 - |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.1.                | the                board of directors of Aspen approves the transaction contemplated                in this                agreement; and |
|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          11 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 4.1.2.                | the                board of directors of Prestige approves the transaction contemplated                in                this agreement. |
|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2.       | Each                of the parties shall, insofar as may be applicable, use all reasonable                commercial endeavours to procure the fulfilment of the prerequisite                conditions. |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3.      | Each                of the prerequisite conditions are expressed to be for the benefit                of both                parties and may be waived only by unanimous written agreement between                the                parties at any time prior to the date for the fulfilment thereof,                provided                that such waiver is competent in terms of the applicable                laws. |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4.       | The                parties shall be entitled to extend the time period for the fulfilment                of                any of the prerequisite conditions by written agreement prior to                the                expiry of any time period for fulfilment of any of the unfulfilled                prerequisite condition/s, provided that such extension of time is                competent in terms of the applicable                laws. |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.5.       | If                any prerequisite condition is validly waived, it shall be deemed                to have                been fulfilled. |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.       | If                any prerequisite condition is not fulfilled for any reason other                than as a                result of a breach of 4.2 - |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.1.                | the                whole of this agreement (other than 1, 2, 3, this 4 and 9 to 19 by                which                the parties shall continue to be bound) shall have no force or effect;                and |
|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.2.                | no                party shall have any claim against any other in terms of this agreement                except for such claims, if any, as may arise from a breach of any                provision of this agreement by which the parties remain bound. |
|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  5.       **  ** | **FACILITY** |
|--------------------------------------------------------------------|--------------|

|                 5.1.        | Pharmacare                will construct and commission the facility so as to enable Pharmacare                to                manufacture the products in accordance with the terms and subject                to the                conditions set out in this                agreement. |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2.        | Pharmacare                undertakes to use its best endeavours to procure                that: |
|------------------------------------------------|-------------------------------------------------------------------------------------------------|

----

|   |                                                                                          12 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 5.2.1.                 | by                1 January 2008, the facility will be capable of commencing the process                of                validating the bulks; |
|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2.2.                 | by                1 July 2008, the bulks will be validated;                and |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|

| 5.2.3.                 | by                1 January 2009, the facility will be commissioned and capable of                manufacturing the products in those quantities set out in **clause                7.5.1**. |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3.        | Notwithstanding                the aforesaid, Pharmacare will use its best endeavours to commence                manufacturing the products as early as is practically                possible. |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.          | **INTERIM                PERIOD AND ALTAIRE** |
|----------------------------------------------------------|-----------------------------------------------|

| 6.1.       | Medtech                acknowledges that it is unlikely that Pharmacare will be capable                of: |
|------------------------------------------|------------------------------------------------------------------------------------------------------------|

| 6.1.1.                | manufacturing                the products for commercial sale prior to 1 July 2008;                and |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|

| 6.1.2.                | meeting                all of Medtech’s requirements for the products prior to 1 January                2009. |
|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|

| 6.2.       | Accordingly,                Medtech will be obliged to secure its own supply of the products                during                the interim period, this by: |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.1.                | attending                to a stock build-up of the products and extending the products shelf                life;                and/or |
|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.2.                | purchasing                the products from Altaire or another                supplier. |
|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|

| 6.3.       | During                the interim period, Medtech may elect to purchase certain of its                requirements of the products from Pharmacare, on the terms and subject                to                the conditions set out in this agreement, to the extent agreed between                the                parties, in writing, from time to time. During the interim period                Medtech                shall not be required to purchase its requirements from Pharmacare                if such                purchase would violate the terms of any agreement with Altaire or                another                supplier. |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 6.4       | Pharmacare shall contribute the maximum sum of US$250,000.00 (two              hundred and fifty thousand United States Dollars) towards Altaire's              process validation |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              13 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|   | costs                in relation to the products so as to facilitate Altaire's ability                to act                as a back-up supplier in accordance with the provisions of **clause                6.6.2** and thereafter during the entire term.  The aforesaid                sum of US$250,000.00 (two hundred and fifty thouseand United States                Dollars) shall constitute the maximum amount payable by Pharmacare                to                Medtech in reimbursement of such costs and such payment shall be                subject                to - |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              14 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.           | **MATERIAL                TERMS OF THE SUPPLY                AGREEMENT** |
|----------------------------------------------------------------|--------------------------------------------------------------------------|

| 7.1.*      * | ***Supply*** |
|--------------------------------------------|--------------|

| 7.1.1.                 | Subject                to **clauses                7.5**                and/or **7.19.1**,                during the exclusive supply term and the extended period/s (if any),                Pharmacare will exclusively sell and supply the products to Medtech,                which                will exclusively purchase all of Medtech and its affiliates’ requirements                of the products for the territory from Pharmacare on the terms and                subject                to the conditions set out                hereunder. |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.2.                 | For                clarification purposes it is recorded that neither party has any                rights                and/or obligations against the other party in relation to                - |
|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.2.1.                          | the                manufacture, supply and/or purchase of any products which will be                marketed, distributed and/or sold in any geographical area, other                than the                territory (unless the territory is expanded by written agreement                between                the parties); and/or |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.2.2.                          | any                products, other than the products as defined (unless Pharmacare exercises                its rights of first refusal in terms of **clause                7.2**). |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.*      * | ***Right                of First Refusal*** |
|--------------------------------------------|---------------------------------------------|

| 7.2.1.                  | Should                Medtech and/or its affiliates at any time during the term                - |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|

| 7.2.1.1.                          | intend                to market, distribute and/or sell additional sterile liquid eye care                products or extensions to the products anywhere in the territory                (“the                **new                products**”);                and/or |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.1.2.                          | require                the manufacture of the products and/or new products for marketing,                distribution and/or sale outside of the territory (“the **external                territory**”) |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**offer      notice**

----

| 7.2.2.                 | The                offer notice shall - |
|--------------------------------------------------------------------------------------------------------|-----------------------------------------|

| 7.2.2.1.                          | set                out the precise specifications of the new products and their primary                packaging and/or the intended jurisdiction of their sale;                and |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.2.2.                          | state                the price at which Medtech proposes to purchase the new products                and/or                the products in relation to the external                territory. |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.3.                 | For                a period of 90 (ninety) days from the receipt of the offer notice,                Pharmacare shall have the irrevocable right and option to elect to                manufacture, supply and sell the new products and/or the products                in                relation to the external territory at the price set out in the offer                notice read together with the terms and conditions set out in this                agreement. |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.4.                 | In                the event of Pharmacare not accepting its irrevocable right and option                set                out in the offer notice within the aforesaid period of 90 (ninety)                days,                it shall be deemed to have declined the same and Medtech and/or its                affiliates shall then have the right to purchase the new products                and/or                the products in relation to the external territory from a third party                of                its choice, provided that the price thereof shall not be higher than                the                price set out in the offer notice. |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.5.                 | The                provisions of this **clause                7**                shall not apply in circumstances where Medtech and/or its affiliates                do                not have the legal and/or contractual competence to procure the                manufacture of the new products and/or the manufacture of the products                for                marketing, distribution and/or sale in the external territory by                Pharmacare. Medtech hereby undertakes to Pharmacare to use its best                endeavours, in all circumstances, to obtain such legal and/or contractual                competence. |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.*      * | ***Purchase                price/s*** |
|--------------------------------------------|---------------------------------------|

| 7.3.1.                 | Medtech                shall purchase the products from Pharmacare at the purchase price/s                (“the                **purchase                price/s**”)                set out in **Exhibit                D**. |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                           16 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.3.2.                 | The                purchase price/s are ex-works. |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------|

| 7.3.3.                 | The                purchase price/s shall - |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------|

| 7.3.3.1.                          | include |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|

| 7.3.3.1.1.                             | the                costs of conversion as set out in **Exhibit                D**                as                adjusted, from time to time, in accordance with the provisions of                **clauses                7.3.4**                and/or **7.3.5**; |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.3.1.2.                             | the                costs of primary packaging; |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|

| 7.3.3.1.3.                             | the                costs of raw material; |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|

| 7.3.3.1.4.                             | the                costs of providing stability services;                and |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|

|  7.3.3.1.5.                            | the                costs of providing the regulatory                support; |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|

| 7.3.3.2.                        | exclude |
|----------------------------------------------------------------------------------------------------------------------------------------------------|---------|

| 7.3.3.2.1.                              | the                costs of secondary packaging; and |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|

| 7.3.3.2.2.                              | the                costs of delivery. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|

| 7.3.4.                | The                purchase price/s shall be increased - |
|--------------------------------------------------------------------------------------------------|----------------------------------------------------------|

| 7.3.4.1.                    | in                relation to the costs of conversion on 1 January 2010 and on 1 January                of                each succeeding year taking into account price affecting factors,                such as                variations in Pharmacare’s costs of labour, energy, increases in taxes and                all other relevant factors affecting Pharmacare’s conversion costs in                manufacturing the products; |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.4.2.                    | in                relation to the costs of all other components as set out in **clauses                7.3.3.1.2, 7.3.3.1.3, 7.3.3.1.4 and 7.3.3.1.5**                on                the earlier of 1 January 2009 or the date of first supply of the                products                to Medtech and on 1 January of each succeeding year taking into |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          17 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|   |             account              the actual increase in Pharmacare's costs of procuring and/or rendering              the same. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.3.5.          | No                later than 60 (sixty) days prior to each purchase price increase,                Pharmacare shall submit reasonable documentary proof of the factors                affecting such increases to Medtech and enter into consultations                with                Medtech in relation thereto. |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.6.          | Notwithstanding                the provisions of **clause                7.3.4**                increases in the purchase price/s shall be moderated (“the moderation”) by                - |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.6.1.                  | manufacturing                process improvements achieved, from time to time, by Pharmacare in                relation to the manufacture of the products. Pharmacare undertakes                to use                its best endeavours to achieve such improvements;                and |
|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.6.2.                    | those                cost efficiencies which will accrue to Pharmacare in the event of                Medtech                purchasing more than 28 000 000 (twenty eight million) units of                the products from Pharmacare during any calendar year of the                term. |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.7              | No                price increase shall be effective unless and until Pharmacare has                provided                at least 60 days notice in writing to                Medtech. |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4.*   * | ***Forecasts/Firm                Orders*** |
|--------------------------|--------------------------------------------|

| 7.4.1.            | Unless                otherwise agreed in writing by the parties, Medtech shall on a monthly                basis provide Pharmacare with a rolling forecast of its requirements                for                the products for an 18 (eighteen) month period (the “**rolling                forecast**”).                All rolling forecasts and any updates to such rolling forecasts shall                be                updated on a monthly basis and provided to Pharmacare by the 10 (tenth)                business day of each month, for the 18 (eighteen) month period commencing                on the first day of the immediately following                month. |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          18 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.4.2.          | Medtech’s                requirements of the products during the first 3 (three) months of                the                rolling forecast (“the                **firm order period**”)                shall be considered a firm order (in that Medtech will be required                to                purchase and Pharmacare shall be required to supply the products)                (the                “**firm                order**”)                unless agreed otherwise by the parties in writing. Firm orders each                month                shall be in accordance with the multiple order quantity of that product’s                manufacture batch size (that is, in whole multiple manufacture batch                sizes                and not fractions thereof). |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4.3.          | Pharmacare                shall order sufficient quantities of the inventory to enable it to                manufacture the products in accordance with Medtech’s requirements for                firm orders. |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.     | ***Quantities                of Supply and Exclusive                Purchase*** |
|------------------------------|---------------------------------------------------------------------------------|

| 7.5.1.           | Notwithstanding                any other provisions of this agreement during each calendar year                Pharmacare shall not be obliged to supply more than 30 000 000                (thirty million) units of the products and, in any event, not more                than                - |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.1.1.           | 9 000 000                (nine million) units of the products which are 0.2 (nought point                two)                ounces and/or 10 (ten) millilitres in                size; |
|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.1.2.                 | 3 000 0000                (three million) units of the products which are 1 (one) ounce in                size; |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|

| 7.5.1.3.                 | 24 000 000                (twenty four million) units of the products which are 0.5 (nought                point                five) ounces in size. |
|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.2.          | Subject                to **clauses                7.5**                and **7.19.1**,                Medtech shall, during the exclusive supply term and the extended                period/s                (if any), be obliged to purchase all of Medtech and its affiliates’                requirements of the products for the territory exclusively from Pharmacare                on the terms and subject to the conditions set out in this                agreement. |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5.3.          | Notwithstanding                any other provision of this agreement, should Medtech require in                excess of                30 000 000 (thirty million) units of the products during |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          19 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|   | any                calendar year and/or products in excess of the threshold set out                in                **clause                7.5.1**                (“the **additional                products**”),                then Medtech shall give notice, in writing (the**invitation                notice**”)                to Pharmacare of its requirements for the additional products and                Pharmacare shall, for a period of 30 (thirty) days from the date                of                receipt of the invitation notice, have the irrevocable right and                option to                elect to manufacture, sell and supply the additional products to                Medtech                on the terms and subject to the conditions set out in this agreement.                In                the event of Pharmacare failing to accept the irrevocable right and                option                set out in the invitation notice, then it shall be deemed to have                declined                the same and Medtech shall be entitled to purchase the additional                products                from a third party of its choice. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.6.         | ***Delivery*** |
|------------------------------------------------------|----------------|

| 7.6.1.                  | Pharmacare                shall deliver each firm order of each product in the quantities and                within                the delivery dates directed by Medtech as specified in the firm order,                at                Medtech’s expense. A firm order will be considered complete if it is                within a tolerance of + or - 5% (five percent) of the ordered quantity.                Any deviation greater than + or - 5% (five percent) needs to be agreed                in                writing between the parties. |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6.2.                  | Pharmacare                shall ensure that all products supplied under this agreement, other                than                validation batches, shall have their relevant registered shelf-life,                less                a maximum of 90 (ninety) days, at the date of delivery thereof (ex-works)                unless otherwise agreed in writing between the                parties. |
|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6.3.                  | Delivery                will be considered on time if the products are delivered (as determined                in                accordance with INCOTERM ex-works) at anytime during the month for                delivery. |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6.4.                  | Pharmacare                shall arrange the delivery of each order of the product to the location                as                agreed, in writing, between the                parties. |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7.*       * | ***Specifications*** |
|--------------------------------------------------|----------------------|

| 7.7.1.                  | Changes                may be made in the specifications as required to maintain the product                for                sale in the territory, subject to written agreement between the |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                         20 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|               | parties                and compliance with cGMP’s. Medtech shall notify Pharmacare as far in                advance as is practicable prior to the effectiveness of such amendment                or                change and Pharmacare shall promptly notify Medtech of the implementation                of any such amendment or change. To the extent that such amendment                or                change results in an increase or reduction in the cost of manufacturing                a                product, the parties shall jointly examine and mutually agree upon                the                consequences thereof and shall make appropriate adjustments to the                purchase price/s, save as otherwise agreed in writing any such increase                in                the purchase price/s shall be borne by                Medtech. |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.7.2.                  | Changes                in the specifications requested by Medtech in relation to product                improvements and the like shall require Pharmacare’s prior written                consent, which consent shall not be unreasonably withheld. To the                extent                that such changes result in an increase or reduction in the costs                of                manufacturing a product, the parties shall jointly examine and mutually                agree upon the consequences thereof and shall make appropriate adjustments                to the purchase price/s. Save as is otherwise agreed in writing any                such                increase in purchase price/s shall be borne by Medtech. Medtech shall                also                be liable for and shall pay for the costs of amending the know-how                and/or                intellectual property as a consequence of such changes to the                specifications, including but not limited to validation and                stability. |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7.3.                  | Medtech                and Pharmacare shall cooperate to ensure that the specifications                and other                instructions provided by Medtech are and shall, at all times, be                in                accordance with the marketing authorisations for each product.                Notwithstanding the aforesaid, Medtech shall be solely responsible                for                ensuring that the specifications and all instructions given to Pharmacare                are, at all times, in accordance with the marketing authorisation                for each                product and the applicable laws. Medtech shall be solely liable for                any                omissions and/or shortcomings in relation to the marketing authorisations                for each product. |
|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.8.*       * | ***Acceptance                of Delivery*** |
|--------------------------------------------------|---------------------------------------------|

| 7.8.1.                 | Medtech                shall, within a period of 30 (thirty) business days of receipt of                products                delivered to it (or its nominee) by Pharmacare have the right to |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          21 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

|               | reject                any such products as a consequence of them being defective or where                the                products delivered are outside the quantity tolerance specified in                **clause                7.6.1**.                If Medtech does not notify Pharmacare of its election to reject the                products within the aforesaid period of 30 (thirty) business days,                then                the products delivered will be deemed to have been accepted by Medtech                unless the defect is latent. |
|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.8.2.                 | In                addition to the rights to return defective products in **clause                7.8.1**,                following the date of delivery of a product to Medtech (or its nominee),                Medtech shall be entitled to return products still in the possession                or                under the control of Medtech in the event that latent defects in                such                products later become evident. |
|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.8.3.           | Any                quantities of the products which are properly rejected and/or returned                by                Medtech in accordance with the provisions of this agreement shall                be                returned to Pharmacare at Pharmacare’s expense and at Pharmacare’s                option: |
|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.8.3.1.               | the                products shall be replaced by Pharmacare as quickly as possible at                Pharmacare’s sole expense; or |
|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| 7.8.3.2.               | Pharmacare                shall refund the purchase price/s then paid to it by Medtech in respect                of                those products. |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.       | ***Terms                of Sale*** |
|------------------------------------------|------------------------------------|

| 7.9.1.           | The                products shall be delivered ex-works and accordingly the purchase                price/s                therefor excludes the costs and expenses associated with delivery                and                secondary packaging. The parties undertake to co-operate to do all                things                reasonably practicable to ensure the reliable and economic delivery                of the                products to Medtech. |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.2.           | Unless                otherwise agreed by the parties in writing, Pharmacare shall be                responsible for making the delivery arrangements on behalf of Medtech.                The                parties shall annually in advance (or at such other times as agreed)                agree                delivery arrangements for the supply during that year (or other relevant                following period). |
|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          22 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.9.3.           | All                or any direct costs and expenses incurred by Pharmacare in respect                of the                actual delivery of the products and in relation to secondary packaging                shall be reimbursed by Medtech to Pharmacare simultaneously with                the                payment of the purchase price/s for the products in                question. |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.4.           | Pharmacare                shall issue an invoice with each delivery of product in respect of                the                purchase price/s of such products which invoice will include the                costs and                expenses of delivery and/or secondary packaging referred to in                **clause                7.9.3**                above and Medtech agrees to pay such invoice by wire transfer arranged                through an United States bank, payable within 60 (sixty) days from                the                issue of the invoice. |
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.5.           | All                payments of the purchase price/s or other sums payable by Medtech                shall be                made without any set-off in a timely fashion. Any amount due to Pharmacare                and not paid within the required period shall be subject to interest                charged at the prime rate (both before and after any judgement) calculated                from the date the payment of the relevant sum was due to the date                it is                paid in full (inclusive). |
|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.6.           | The                risk of loss, damage, destruction of products shall pass to Medtech                when                the products are delivered (as determined in accordance with the                INCOTERM                ex-works). |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.7.           | The                legal and beneficial title to the products shall transfer to Medtech                on                the date Pharmacare has received payment in full and in cleared funds                of                the purchase price/s for the                products. |
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.10.       | ***Medtech’s                Intellectual Property*** |
|-------------------------------------------|------------------------------------------------------------|

| 7.10.1.           | trademarks;                and |
|---------------------------------------------------------------------|--------------------------------|

| 7.10.2.           | the                intellectual property. |
|---------------------------------------------------------------------|-------------------------------------------|

----

|   |                                                                                              23 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.11.       | ***Manufacturing                Issues*** |
|-------------------------------------------|-------------------------------------------|

| 7.11.1.           | If                it is necessary for the purposes of compliance with any applicable                laws                for Pharmacare to make any change to the manufacturing process, procedures                or facilities including changes in or replacement of equipment it                shall so                notify Medtech and Medtech shall as soon as possible make all such                changes                to the marketing authorisation, through application to the relevant                governmental or regulatory authority and Pharmacare shall, at Medtech’s                cost and expense (which costs and expenses shall be paid for by Medtech                and/or reimbursed to Pharmacare by Medtech against demand), supply                data                which Medtech reasonably requires for such                purpose. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.2.           | Pharmacare                warrants to Medtech that it will manufacture each product in compliance                with the specifications for such product and in accordance with good                manufacturing practices, the marketing authorisations and the provisions                of the technical agreement. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.3.           | Pharmacare                will, at its cost and expense, maintain all necessary manufacturing                authorisations to manufacture the                products. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.4.           | Pharmacare                will be responsible for creating and retaining all records relating                to the                manufacture of the product as required by the applicable laws and                confirmed in the technical                agreement. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.5.           | Pharmacare                shall, at its cost and expense, conduct all necessary validation                and                routine maintenance stability studies in respect of the                products. |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.6.           | Pharmacare                shall be responsible for procuring all inventory for each product.                All                inventory procured by Pharmacare and used in the products shall be                tested                (by Pharmacare or the supplier thereof) to assure that they meet                the                specifications and quality                standards. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.7.           | Pharmacare                shall supply products bearing the trademarks and Medtech’s marketing                authorisation number and Medtech shall be responsible for determining                the                contents and appearance of the product containers, |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          24 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|                | labels, inserts and packaging materials in relation to the primary              packaging. |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.11.8.           | Pharmacare                shall make changes to the appearance of the primary packaging as                requested                by Medtech from time to time. Pharmacare will make no change to the                primary packaging without the prior written approval of Medtech.                All                increases in costs associated with changes to the primary packaging,                including but not limited to stability tests to support such changes,                shall be added to and incorporated into the purchase price/s of the                products. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.11.9.           | In                order that Pharmacare can make the necessary preparations for the                commencement of manufacture of each product (and primary packaging)                bearing Medtech’s name and logo Medtech shall provide Pharmacare with                copies of the necessary artwork, materials and other information                required                by Pharmacare a reasonable period prior to the commencement of their                production in accordance with Pharmacare’s reasonable                lead-times. |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.12.       | ***Product                Optimisation and Line                Extensions*** |
|-------------------------------------------|------------------------------------------------------------------------------|

| 7.12.1.           | The                parties will meet twice annually in order to evaluate Medtech’s                requirements for the development of product optimisations and line                extensions (“the **development                work**”)                for the ensuing 12 (twelve) month period. The meeting site will alternate                between Port Elizabeth, South Africa and Irvington, New                York. |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.12.2.           | Within                30 (thirty) days of Medtech’s requirements for the development work having                been determined, Pharmacare shall have the right to submit a quote                to                Medtech to undertake the whole or part of the development work and                simultaneously therewith Pharmacare shall give to Medtech the anticipated                date/s by which Pharmacare will be in a position to complete the                same. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.12.3.           | In                the event of Medtech and Pharmacare failing to reach agreement on                any                issue relevant to the development work and/or Pharmacare failing                to timely                submit its proposals to Medtech in that regard, Medtech shall be |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                               25 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|              | entitled to engage a third party of its choice to undertake the              development work without recourse to or from              Pharmacare. |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.13.*      * | ***Adverse                Drug Reaction, Competent Authorities and Product                Recall*** |
|---------------------------------------------|-----------------------------------------------------------------------------------------------------|

| 7.13.1.           | Medtech                will be responsible for reporting any adverse event in particular,                without                limiting the generality of the aforegoing, any serious adverse event                unless otherwise agreed, in writing, between the                parties. |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.13.2.           | Pharmacare                shall, immediately upon receipt of any communication from any governmental                or regulatory authority relating to each product, forward a copy                or                description of the same to Medtech and respond to all inquiries by                Medtech                relating thereto. If Pharmacare must communicate with any governmental                or                regulatory authority, then Pharmacare shall so advise Medtech immediately,                and, unless prohibited by the applicable law, provide Medtech in                advance                with a copy of any proposed written communication and comply with                any and                all reasonable direction of Medtech concerning any meeting or written                or                oral communication with any governmental or regulatory                authority. |
|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.13.3.           | Medtech                shall have sole responsibility for and shall make all decisions with                respect to any complaint, recall, market withdrawals or any other                corrective action related to the                products. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.14.*      * | ***Delivery                of Know-How and Intellectual                Property*** |
|---------------------------------------------|------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

|   | The                parties shall agree, in the strategic plan, the process                and timing of the delivery of the know-how and intellectual property                by                Medtech to Pharmacare which know-how and intellectual property shall                include but not be limited to a technical data pack in respect of                each of                the products containing at least the vendor details, specifications                and                test methods for active pharmaceutical ingredients and excipients,                vendor                details, specifications and test methods for primary packaging, detailed                requirements of printed primary packaging, detailed manufacturing                and                primary packing instructions, secondary packaging instructions, validation                parameters and previous reports, finished product specifications                and test                methods, validations and/or system suitability data, stability  |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.15.*      * | ***Warranties                by Medtech*** |
|---------------------------------------------|--------------------------------------------|

| 7.15.1.           | the                know-how and/or knowledge relating to the intellectual property will                be                disclosed and/or imparted to Pharmacare on the date/s set out in                the                strategic plan and will be sufficient, without the necessity of Pharmacare                undertaking further work thereon other than process validation and                expiration dating, to manufacture the products in accordance with                the                manufacturing authorisations, the marketing authorisations and the                applicable laws; |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.15.2.           | neither                the trademarks or the primary packaging will, throughout the term,                infringe the rights, including the intellectual property rights,                of any                person or entity when delivered to Medtech for sale in the                territory; |
|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.15.3.           | the                transfer of the know-how and intellectual property to Pharmacare                will not                infringe the rights, including the intellectual property rights,                of any                person or entity and it will, throughout the term, have the exclusive                legal and beneficial interest in the know-how and related                information; |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.15.4.           | provided                that the products have been manufactured by Pharmacare in compliance                with                their specifications and in accordance with good manufacturing practices                and all applicable laws will not whether, by their use or administration                or otherwise, cause any adverse event and, in particular, without                limiting                the generality of the aforegoing, any serious adverse event;                and |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.15.5.           | it                will purchase from Pharmacare no less than those quantities of the                products as set out in **clause                7.5.2.** |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              27 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.16.    *  * | ***Strategic                Plan*** |
|---------------------------------------------|-------------------------------------|

| 7.16.1.           | As                soon as is practicably possible after the effective date, the parties                will                meet and do all things necessary, in good faith, to develop a strategic                plan in relation to, *inter                alia*                - |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.16.1.1.          | the                method and timing of the delivery and transfer of the know-how and                intellectual property to                Pharmacare; |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.16.1.2.             | the                transitional plan incorporating the supply of the products by Pharmacare                to Medtech during the interim period and the transfer of the manufacture                of the products from Abbott Laboratories Inc. to Pharmacare and where                necessary Altaire; |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.16.1.3.             | the                method and timing of the commissioning of the facility and each part                of                that facility; |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 7.16.1.4.             | the                method and timing of the validation and the proposed order of such                validation; and |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|

| 7.16.1.5.             | the                arrangements for the delivery of the products to the locations agreed,                in                writing, between the parties. |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.16.2.           | The                parties shall be obliged to allocate and dedicate, at their respective                cost and expense, sufficient resources and skilled personnel to ensure                that the strategic plan promotes and establishes a sound and enduring                business relationship between the parties on the terms and subject                to the                conditions set out in this                agreement. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.17.*      * | ***Regulatory                Support*** |
|---------------------------------------------|-----------------------------------------|

| 7.17.1.         * * | Notwithstanding                the purchase price/s being inclusive of regulatory support, Medtech                shall,                at all times, and without limitation be solely responsible to ensure                that                all activities and processes relating to the maintenance and updating                of                the marketing authorisations are timely and comprehensively undertaken                in                accordance with the applicable                laws. |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          28 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.17.2.           | Pharmacare’s                obligations in relation to regulatory support shall include allocation,                in                the Republic of South Africa, of one of its suitably qualified                representatives to assist Medtech in undertaking the compliance activities                and processes relating to the maintenance and updating of the marketing                authorisations in so far as the activities relate to the purchasing                of                inventory, production, quality control and assurance, filling, labelling,                packaging and finishing, release, holding and storage of the products;                under the direct supervision, instruction and control and at the                risk of                Medtech and which includes the grant of the rights of use to Medtech                of                Pharmacare’s equipment and consumables incidental thereto. In no event                shall Pharmacare be liable in contract, tort (including negligence)                or                breach of statutory duty or otherwise, including pursuant to an indemnity                for any loss or damage of whatever nature whatsoever arising out                of or in                connection with the failure to maintain and/or update the marketing                authorisations in accordance with the applicable                laws. |
|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.17.3.                                         | Medtech                hereby indemnifies Pharmacare against any liability for loss (excluding                economic loss), damage or injury (including death) whether direct,                indirect or consequential suffered by any person or entity not being                a                party to this agreement resulting from or arising out of the failure                to                maintain and/or update the marketing authorisations in accordance                with the                applicable laws. |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.17.4.           | Pharmacare                hereby indemnifies Medtech against any liability for loss (excluding                economic loss), damage or injury (including death) whether direct,                indirect or consequential suffered by any person or entity not being                a                party to this agreement resulting from or arising out of the failure                of                Pharmacare to meet specifications or to follow the requirements of                cGMP’s. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.18.       | ***Liability*** |
|-------------------------------------------|-----------------|

----

|   |                                                                                          29 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.18.1.           | any                indirect or consequential loss of or damage of any nature whatsoever;                or |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|

| 7.18.2.           | save                as is expressly provided for in **clauses                7.19.2**,                any loss of profit, pure economic loss, depletion of goodwill, loss                of                business or like loss (whether direct or indirect);                or |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.18.3.           | any                claim/s by the other party (inclusive of indemnities by either party)                irrespective of the nature or cause of such claim/s which alone or                in                aggregate exceed US$50,000,000.00 (fifty million United States                Dollars), |
|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.    *  * | ***Remedies*** |
|---------------------------------------------|----------------|

| 7.19.1.           | Provided                that Pharmacare has used its best endeavours to timeously deliver                the                products to Medtech on the terms and subject to the conditions set                out in                this agreement, then Medtech shall have no claims against Pharmacare                arising out of or flowing from such non-delivery. In all instances                where                Pharmacare fails to timeously deliver any of the products to Medtech                (“the                **undelivered                products**”),                Medtech shall be obliged to use its best endeavours (for so long                as                Pharmacare remains in breach of its obligations to so supply the                products), to purchase the undelivered products from Altaire and/or                another supplier of its choice. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.2.           | Subject                to **clause                7.19.4**,                in the event of Medtech failing to purchase all of Medtech and its                affiliates’ requirements of the products exclusively from Pharmacare                - |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.2.1.                          |     during                the 12 (twelve) month period commencing on 1 January 2009 and terminating                on 31 December 2009, then Medtech shall pay     to Pharmacare                a compensation fee in the sum of US$5,000,000.00 (five million United                States Dollars); |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.2.2.              | during                the 12 (twelve) month period commencing on 1 January 2010 and terminating                on 31 December 2010, then Medtech shall |
|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                  30 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|  |   pay to Pharmacare a compensation fee in the sum of              US$4,000,000.00 (four million United States              Dollars); |
|--|-------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 7.19.2.3.              | during                the 12 (twelve) month period commencing on 1 January 2011 and terminating                on 31 December 2011, then Medtech shall pay to Pharmacare a compensation                fee in the sum of US$4,000,000.00 (four million United States                Dollars); |
|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.2.4.               | during                the 12 (twelve) month period commencing on 1 January 2012 and terminating                on 31 December 2012, then Medtech shall pay to Pharmacare a compensation                fee in the sum of US$3,000,000.00 (three million United States                Dollars); |
|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.2.5.               | during                the 12 (twelve) month period commencing on 1 January 2013 and terminating                on 31 December 2013, then Medtech shall pay to Pharmacare a compensation                fee in the sum of US$3,000,000.00 (three million United States                Dollars). |
|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.3.           | The                compensation fee/s referred to in **clause                7.19.2.1**                to                **clause                7.19.2.5**                shall be jointly and/or individually referred to as “the **Pharmacare                compensation fee/s**”.                Medtech agrees that the Pharmacare compensation fee/s is in consideration                for, amongst other things, the construction of the facility by Pharmacare                in order to supply the products to Medtech on the terms and subject                to the                conditions set out in this                agreement. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.4.           | The                Pharmacare compensation fee/s shall not be payable                - |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------|

| 7.19.4.1.               | should                Medtech and/or its affiliates have purchased 30,000,000 (thirty million)                units of the products from Pharmacare during any of the relevant                calendar                years or such greater volumes as may have been agreed to between                the                parties, from time to time; and/or |
|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.4.2.               | in                circumstances where Pharmacare is not able to supply the relevant                products                to Medtech. |
|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          31 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.19.5.           | The                Pharmacare compensation fee shall be due, owing and payable by Medtech                to                Pharmacare within 30 (thirty) days of the date of Medtech and/or                its                affiliates’ breach of the provisions of **clause                7.19.2**                and shall be payable without demand, deduction or                set-off. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.           | In                the event of Pharmacare not being able to fulfil its obligations                to                Medtech in terms of this agreement as a consequence of Pharmacare                allocating the manufacturing capacity of the facility for the purposes                of                manufacturing products for any third party                - |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.1.               | during                the 12 (twelve) month period commencing on 1 January 2009 and terminating                on 31 December 2009, then Pharmacare shall pay to Medtech a compensation                fee in the sum of US$5,000,000.00 (five million United States                Dollars); |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.2.               | during                the 12 (twelve) month period commencing on 1 January 2010 and terminating                on 31 December 2010, then Pharmacare shall pay to Medtech a compensation                fee in the sum of US$4,000,000.00 (four million United States                Dollars); |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.3.               | during                the 12 (twelve) month period commencing on 1 January 2011 and terminating                on 31 December 2011, then Pharmacare shall pay to Medtech a compensation                fee in the sum of US$4,000,000.00 (four million United States                Dollars); |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.4.               | during                the 12 (twelve) month period commencing on 1 January 2012 and terminating                on 31 December 2012, then Pharmacare shall pay to Medtech a compensation                fee in the sum of US$3,000,000.00 (three million United States                Dollars); |
|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.6.5.               | .during                the 12 (twelve) month period commencing on 1 January 2013 and terminating                on 31 December 2013, then Pharmacare shall pay to Medtech a compensation                fee in the sum of US$3,000,000.00 (three million United States                Dollars). |
|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                          32 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.19.7.           | The                compensation fee/s payable by Pharmacare to Medtech in terms of                **clause                7.19.6**                shall jointly and/or individually be referred to as “the **Medtech                compensation fee/s**”. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.8.           | The                Medtech compensation fee shall be due, owing and payable by Pharmacare                to                Medtech within 30 (thirty) days of the date of Pharmacare breaching                the                provisions of **clause                7.19.6**                and shall be payable without demand, deduction or                set-off. |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.9.           | In                the event of Medtech failing to pay the full purchase price/s for                the                products and/or the Pharmacare compensation to Pharmacare on due                date,                then Pharmacare shall be entitled to immediately suspend the further                supply of the products (“the **suspended                products**”)                to Medtech, on written notice to Medtech, this until such time as                the                outstanding purchase price/s and/or the Pharmacare compensation,                together                with accrued interest thereon, has been paid in full. The failure                by                Pharmacare to deliver the suspended products shall not give rise                to a                breach of this agreement by                Pharmacare. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.10.          | Any                amounts which are due by one party to the other party in terms of                this                agreement which are not paid on due date shall accrue interest at                the                prime rate, calculated from due date to date of payment                (inclusive). |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.19.11.           | A                failure by either party to perform or observe any of their remaining                obligations set out in this agreement shall entitle the other party                to                only claim specific performance and damages (subject to the limitations                set out in **clause                7.18**)                and the parties hereby waive and abandon all or any other rights                and                remedies against the other party not expressly set out in this                **clause                7.19.** |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                                33 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.20.    *  * | ***Subcontracting*** |
|---------------------------------------------|----------------------|

| 7.21.       | ***Sale                of Business by                Medtech*** |
|-------------------------------------------|-----------------------------------------------------------------|

| 8.         | **EFFECT                OF TERMINATION OR                EXPIRATION** |
|----------------------------------------------------|-----------------------------------------------------------------------|

| 8.1.       | Upon                expiration or prior termination of this agreement, for any reason,                it                shall not release either party from any liability which at the said                time                it has already incurred to the other party nor affect in any way                the                survival of any rights, duties or obligations of either                party. |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.        | Upon                earlier termination of this agreement, Pharmacare shall supply to                Medtech                and Medtech shall purchase the finished products at their purchase                price/s                and any inventory then in Pharmacare’s possession (or on order by                Pharmacare), this at the cost price/s                thereof. |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3.           | Medtech                shall be liable to pay Pharmacare the purchase price/s for the finished                products and the cost price of the inventory within 14 (fourteen)                days                of                the date of expiration or earlier termination of this agreement or                in                respect of part termination. |
|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              34 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 8.4.       |  Delivery                of the finished products and inventory pursuant to the provisions                of this                **clause                8**                shall be made ex-works. |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.                        | Pharmacare’s                non-transferable, royalty-free, non-exclusive license to use the                trademarks and the intellectual property shall immediately terminate                and                Pharmacare shall have no further rights, title or interest in and                to the                said trademarks or intellectual property and it shall immediately                cease                exercising any rights in relation                thereto. |
|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.         | ** CONFIDENTIALITY** |
|----------------------------------------------------|---------------------------|

| 9.1.        | All                confidential and/or proprietary information of Pharmacare disclosed                to                Medtech and all confidential and/or proprietary information of Medtech                disclosed to Pharmacare including, but not limited to, information                relating to any product or the business affairs or finances of either                party, information contained in the know-how and the terms of this                agreement and/or the supply agreement known hereafter as the “**confidential                information**”                shall be held in confidence and not disclosed by the other party                to any                third party or used, for any reason whatsoever, outside the scope                of this                agreement and/or the supply agreement; provided, that the definition                of                “**confidential                information**”                and the obligation of confidentiality assumed by Medtech and Pharmacare                hereunder shall not apply to any confidential or proprietary information                which was or becomes available to Medtech or Pharmacare, as the case                may                be, on a non-confidential basis from a source that is not under an                obligation (whether contractual, legal or fiduciary) to the other                party to                keep such information confidential. If the party receiving information                of                the other party (the “**receiving                party**”)                is requested in any judicial or administrative proceeding or by any                governmental or regulatory authority to disclose any information                of the                other party (the “**disclosing                party**”),                the receiving party shall give the disclosing party prompt notice                of such                request so that the disclosing party may seek an appropriate protective                order. The receiving party shall cooperate fully with the disclosing                party                in obtaining such an order. If in the absence of a protective order                the                receiving party is nonetheless compelled to disclose confidential                information of the disclosing party, the receiving party may make                such                disclosure without liability hereunder, provided that the receiving                party                gives the disclosing party written notice of the confidential information                to be disclosed as far in advance of its disclosure as is practicable                and,                upon the disclosing party’s request and at its expense, the receiving                party will use its best |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              35 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|           | efforts to obtain reasonable assurances that confidential treatment              will be accorded to such confidential information. |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 9.2.                           | This                **c****lause                9**                shall survive the expiration or termination of this agreement for                a period                of five (5) years. |
|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.        | **RELATIONSHIP                OF PARTIES** |
|-----------------------------------------------|--------------------------------------------|

| 11.         | **ASSIGNMENT** |
|-----------------------------------------------------|----------------|

| 12.         | **FORCE                MAJEURE** |
|-----------------------------------------------------|----------------------------------|

**other      party**

----

|   |                                                                                              36 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|           | continuing for a period of at least 6 (six) months, the other party              shall have the right to terminate this agreement upon 30 (thirty) days              written notice. |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 13.         | **GOVERNING                LAW AND JURISDICTION** |
|-----------------------------------------------------|---------------------------------------------------|

| 13.1.        | The                construction, validity and performance of this agreement shall be                governed                by the laws of the State of New York, United States of                America. |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.2.        | It                is irrevocably agreed that the State and Federal courts located in                the                State of New York, United States of America, are to have non-exclusive                jurisdiction to settle any disputes which may arise out of or in                connection with this agreement and accordingly that any action or                proceeding so arising may be brought in such                courts. |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.         | **NOTICES** |
|-----------------------------------------------------|-------------|

| 14.1.       | Any                notice to be given under this agreement shall be in writing and delivered                personally or sent by first class recorded delivery post or facsimile                to                the address for service of the other party as set out in **clause                13.4**,                or such other address as may have been notified in writing to the                other                party. |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2.       | A                notice shall be deemed to have been served as follows if personally                delivered, at the time of delivery; if posted, at the expiration                of 96                (ninety six) hours after the envelope containing the same was delivered                into the custody of the postal authorities; or if sent by facsimile                at the                expiration of 24 (twenty four) hours after the same was                transmitted. |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.                         | In                proving service of a notice: by delivery by hand: it shall be sufficient                to show that delivery by hand was made; by post: it shall be sufficient                to                show the envelope containing the communication was properly sent                by first                class recorded delivery post; by facsimile transmission: it shall                be                sufficient to show that the facsimile was despatched and a confirmatory                transmission report received. |
|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              37 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 14.4.      | Addresses                for service: |
|-------------------------------------|---------------------------------------|

|                  Pharmacare and Aspen:                  Building 8 Healthcare Park                 Woodlands Drive                 Woodmead                 JOHANNESBURG                 Telefax No. (011) 2396100 **                 With copy to:**                  Aspen Pharmacare Holdings Limited                 1st                Floor Aspen House                 Aspen Park                 98 Armstrong Avenue                 La Lucia Ridge                 Durban                 Telefax No. (031) 5808640                  Marked for the attention of **The                Deputy****                 Group Chief Executive**  |                  Medtech:                  Medtech Products, Inc.                 Attn: CEO                 90 North Broadway                 Irvington, New York 10533                 Telefax (No 001) 914-524-6810  **                 With a copy to:**                  Prestige Brands Holdings, Inc.                 Attn: General Counsel                 90 North Broadway                 Irvington, New York 10533                 Telefax (No. 001) 914-524-7488  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.                        | **ANNOUNCEMENT** |
|-------------------------------------------------------------------------|------------------|

| 16.                        | **PRESTIGE                SURETYSHIP** |
|-------------------------------------------------------------------------|----------------------------------------|

| 16.1.       | By                its signature hereto, Prestige hereby binds itself in favour of Pharmacare                as surety for and co-principal debtor *in                solidum*                with Medtech for the due and punctual payment and performance by                Medtech                of all of its obligations pursuant to this agreement and/or any suretyship                which Medtech may exercise in favour of Pharmacare in accordance                with the                provisions of **clause                7.21**                and, without restricting the generality of the aforegoing - |
|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.1.1.           | for                any claim/s under any indemnity given by Medtech to                Pharmacare; |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|

| 16.1.2.           | for                the payment of the Pharmacare compensation (**clause                7.19.2**);                and/or |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|

| 16.1.3.           | for                the payment of any damages which Pharmacare may suffer as a result                of, or                in connection with any breach by Medtech of any provisions of this                agreement and/or any suretyship which may be given by Medtech in |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              38 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|               | favour of Pharmacare in accordance with the provision of              **clause 7.21**. |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| 16.2.            | The                suretyship referred to in **clause                16.1**                shall remain of full force and effect and fully binding notwithstanding                - |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.2.1.             | any                amendment/s to this agreement and/or any other agreement from time                to time                subsisting between the parties; |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.2.2.             | any                indulgence, concession, leniency or extension of time which may be                shown                or given by Pharmacare to Medtech; |
|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.2.3.             | the                receipt by Pharmacare of any dividends, or other benefits in any                liquidation, judicial management or other similar disability of                Medtech; |
|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.2.4.             | any                additional suretyships, guarantees, securities or indemnities acquired                by                Pharmacare in connection with the obligations of Medtech;                and |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.2.5.             | the                liquidation, judicial management or deregistration of Medtech or                any                compromise by Medtech with its creditors                generally. |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.3.           | Prestige                hereby renounces the benefits of the legal exceptions “*non                causa debiti*”,                “*errore                calculi*”,                “excussion”, “division”, “no value received”, and “revision of accounts”,                with the meaning and effect of all of which it declares itself to                be fully                acquainted. |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.4.           | Prestige                hereby warrants that it has a material interest in binding itself                as                aforesaid in favour of Pharmacare. |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.       | **ASPEN                SURETYSHIP** |
|-----------------------------------------|-------------------------------------|

| 17.1.     | By                its signature hereto, Aspen hereby binds itself in favour of Medtech                as                surety for and co-principal debtor *in                solidum*                with Pharmacare for the due and punctual payment and performance                by                Pharmacare of all of its obligations pursuant to this agreement and                without restricting the generality of the aforegoing                - |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                         39 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 17.1.1.           | for                any claim/s under any indemnity given by Pharmacare to                Medtech; |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|

| 17.1.2.           | for                the payment of the Medtech compensation (**clause                7.19.5**);                and/or |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|

| 17.1.3.           | for                the payment of any damages which Medtech may suffer as a result of,                or in                connection with any breach by Pharmacare of any provisions of this                agreement. |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.     | The                suretyship referred to in **clause                17.1**                shall remain of full force and effect and fully binding notwithstanding                - |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.1.            | any                amendment/s to this agreement and/or any other agreement from time                to time                subsisting between the parties; |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.2.                            | any                indulgence, concession, leniency or extension of time which may be                shown                or given by Medtech to Pharmacare; |
|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.3.                            | the                receipt by Medtech of any dividends, or other benefits in any liquidation,                judicial management or other similar disability of                Pharmacare; |
|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.4.           |  any                additional suretyships, guarantees, securities or indemnities acquired                by                Medtech in connection with the obligations of Pharmacare;                and |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.2.5.           |  the                liquidation, judicial management or deregistration of Pharmacare                or any                compromise by Pharmacare with its creditors                generally. |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.3.       | Aspen                hereby renounces the benefits of the legal exceptions “*non                causa debiti*”,                “*errore                calculi*”,                “excussion”, “division”, “no value received”, and “revision of accounts”,                with the meaning and effect of all of which it declares itself to                be fully                acquainted. |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.4.       | Aspen                hereby warrants that it has a material interest in binding itself                as                aforesaid in favour of Medtech. |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                              40 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 18.       | **AFFILIATES** |
|-----------------------------------------|----------------|

| 18.1.     | Medtech                undertakes to Pharmacare that it shall procure that all of its affiliates                are bound by and that they comply with the provisions of this                agreement. |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.2.     | Prestige                undertakes to Pharmacare that it shall procure that all of its affiliates                are bound by and that they comply with the provisions of this                agreement. |
|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.       | **COSTS** |
|-----------------------------------------|-----------|

----

**          **

|                                                                                                                                                                                                        |                                                                                                  | **For                and on behalf of PHARMACARE****LIMITED**                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                                                                                                                                                                                                   |                                                                                             |                                                                                |
|                                                                                                                                                                                                   |                                                                                             |                                                                                |
|                                                                                                                                                                                                        |                  | /s/                Stephen Bradley Saad                                        |
|                                                                                                                                                                                                   |                                                                                             | **STEPHEN                BRADLEY SAAD, **Group                Chief       |
|                                                                                                                                                                                                   |                                                                                                  | Executive,                he warranting by his                signature   |
|                                                                                                                                                                                                   |                                                                                             | that                he is duly authorised hereto                               |
|                                   |                                                                                             |                                                                                |

|   |   |                                                            |
|--------|--------|-----------------------------------------------------------------|
|   |   |                                                            |
|        |   |                                                            |
|   |   |                                                            |
|        |   | **For and on behalf of MEDTECH****PRODUCTS, INC.**              |
|   |   |                                                            |
|        |        |                                                            |
|        |   | /s/ Peter C.              Mann                                  |
|   |   | **PETER C. MANN**, President, he warranting                |
|   |   | by his signature that he is duly authorised                     |
|   |   | hereto                                                          |
|   |   |                                                            |

|   |   |                                                           |
|--------|--------|----------------------------------------------------------------|
|   |   |                                                           |
|        |   |                                                           |
|   |   |                                                           |
|        |   | **For and on behalf of PRESTIGE BRANDS****HOLDINGS, INC.**     |
|   |   |                                                           |
|        |   | /s/ Peter C.              Mann                                 |
|   |   | **PETER C. MANN**, Chief Executive              Officer,  |
|   |   | he warranting by his signature that he is duly            |
|   |   | authorized hereto                                         |
|   |   |                                                           |

----

|   |   |                                                                                                                                                                                                                                                                                                     |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                     |
|        |   | **For and on behalf of ASPEN****PHARMACARE HOLDINGS LIMITED**                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                     |
|        |   | /s/ Stephen              Bradley              Saad                                          |
|   |   | **STEPHEN BRADLEY SAAD**, Group ChiefExecutive, he warranting by his signature that he is duly authorised                hereto                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                                                                                                     |